| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2026 | 5 Feb 2026 |
| Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2026 ,inter alia, to consider and approve 1. Unaudited financial results for the quarter and nine months ended 31.12.2025. 2. Limited Review Report quarter and nine months 31.12.2025. 3. Any other business with the permission of the Chair The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026 The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026 Results for the quarter ended 31.12.2025 Un audited Financial Results for the quarter ended 31.12.2025 (As Per BSE Announcement Dated on:13.02.2026) | ||
| Board Meeting | 13 Nov 2025 | 4 Nov 2025 |
| Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.09.2025. 2. Limited Review Report for quarter ended 30.09.2025. 3. Any other business with the permission of the Chair. Un audited Financials Results for the quarter and half year ended 30.09.2025 (As per BSE Announcement dated on: 13.11.2025) | ||
| Board Meeting | 13 Aug 2025 | 6 Aug 2025 |
| Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve 1. Unaudited Financial Results for the quarter ended 30.06.2025 2. Limited Review Report for the quarter ended 30.06.2025 3. Any other business with the permission of the chair. Unaudited Financial results for the quarter ended 30.06.2025 (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 30 May 2025 | 20 May 2025 |
| Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.2025. 2. Audit Report for quarter and year ended 31.03.2025. 3. Any other business with the permission of the Chair. Board Meeting Outcome (As per BSE Announcement Dated on 30/05/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
